BIOHIT in brief Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit’s mission is “Innovating for Health”. Biohit shoulders its social responsibility by creating innovative new technologies and services that help physicians and research institutions to promote diagnostics and research. They can also prevent diseases of the gastrointestinal tract, exposure to acetaldehyde, human suffering and financial loss, thereby generating wellbeing.

Being a socially responsible company, we feel it is our duty to raise public awareness of acetaldehyde, a group 1 carcinogen, and to innovate and develop the marketing of our products and services, ensuring their maximum availability to the public. Biohit is headquartered in Helsinki and has subsidiaries in China and the UK. Biohit’s Series B share (BIOBV) is quoted on NASDA Q OMX Helsinki since 1999, Small cap/Healthcare.

Innovations Gastrointestinal disorders are a growing worldwide phenomenon that also involves significant medical, ethical and financial issues. Gastrointestinal disorders are also the most common cause of complaints regarding treatment, or insufficient treatment. Such problems are essentially related to issues affecting the general healthcare sector and growing financial constraints caused by the ageing population. GastroPanel, Acetium and ColonView are safe, ethical and costefficient innovations for diagnosing and preventing gastrointestinal diseases and the associated risks.